BofA lowered the firm’s price target on Novo Nordisk (NVO) to DKK 350 from DKK 400 and keeps a Neutral rating on the shares. The firm lowers its EPS forecasts 7%-10% on the company’s weak 2026 guidance, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly falls after Reuters report of $49 monthly weight loss pill
- Hims & Hers to offer copy of Wegovy pill at $49 per month, Reuters reports
- Novo Nordisk price target lowered to $45 from $57 at BMO Capital
- Novo Nordisk price target lowered to DKK 340 from DKK 400 at Citi
- Novo Nordisk CEO: I’m confident from a supply perspective for the Wegovy pill